New Report : Biosimilar Opportunities Evolving Market – Market Research Industry

The long awaited promise of biosimilars takes another step to fulfilment with the first approval in Europe of high-value second generation products. But what products can be expected to follow, who is developing them and what are the hot prospects?
Biosimilars: another milestone passed
At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first monoclonal antibody (mAb) therapies to reach a positive opinion following review via the EMA biosimilars regulatory pathway. This is an important event which heralds a new era of lower-cost biological therapies in Europe.
Table of Content
Foreword & Executive Summary
  • Biosimilars: What Are They and Why
  • Are We Interested?
  • What Is A Biotech Drug?
  • Biosimilars and Biobetters Defined
Product Analysis Each product review which follows covers, where appropriate,
  • Developer/Background
  • Mode of Action
  • Approvals
  • Competition within the Marketplace
  • Patents
  • Sales Trends
First Generation Biosimilars Erythropoietin
  • Epogen/Eprex/Procrit (epoetin alfa)
  • Aranesp (darbepoetin alfa)
  • NeoRecormon (epoetin beta)
  • Mircera (methoxy polyethylene glycolepoetin beta) Biosimilar Erythropoietin
  • Europe
  • USA
  • Rest of the World (Epoetin & Darbepoetin)
  • G-CSF
  • Neupogen (filgrastim)
  • Neulasta (pegfilgrastim)
  • Neutrogin/Granocyte (lenograstim)
  • Biosimilar G-CSF
  • Europe (Filgrastim and Pegfilgrastim)
  • USA
  • Rest of the World

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s